Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Revolution Med shoots for $100M+ IPO — and divulges some secrets about that Warp Drive buyout

2 days ago

At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell

3 days ago

In active shopping mode, Eli Lilly plots one deal per quarter as it scouts 'Dermira-like' assets up to $5B

3 days ago

China’s fourth richest man takes a back seat at the top drugmaker he built

3 days ago

Latest

Peter Ciriello takes over the reins at Vygon USA; Mirum Pharmaceuticals taps Ian Clements to the role of CFO

3 days ago

Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel

3 days ago

Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication

3 days ago

First Chinese biotech on Nasdaq in two years draws $104M

3 days ago

Germany’s IQWiG finds first tumor-agnostic drug provides no added benefit

3 days ago

Hung jury vote leaves FDA with a difficult decision on Durect's non-opioid painkiller

3 days ago

see latest stream

People

#JPM20 exclusive: Olivier Brandicourt follows the Big Pharma CEO path to private equity, joining Blackstone ahead of ...

4 days ago

Celgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available

5 days ago

Warren and Klobuchar say they can lower drug prices without Congress’ help

5 days ago

Startups

Takeda hops onto $61M round for CRISPR player synthesizing Cas9 alternatives

5 days ago

Gates vets at Adjuvant back Codagenix's software-driven approach to recoding RSV, flu, oncolytic viruses and more

6 days ago

RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

Last week

Deals

Neon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal

4 days ago

Galapagos beefs up its fibrosis pipeline, lassoing 4 more programs and taking a stake in small Canadian partner

5 days ago

Still to be approved inclisiran gets red carpet treatment by UK's NHS in deal with Novartis

6 days ago

IPOs

Shooting for $100M IPO, Schrödinger takes the wraps off its five internal drugs and discloses deal details

Last week

Biopharma ends decade with near-record investment — but is it going to the right places?

Last week

What are biopharma companies hiring CROs for these days? PPD spells it out in bid for $100M IPO

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Watch live: Endpoints at #JPM20

Last week

Just how big is the biopharma dealmaking world? In 2019 we saw megabillions in cash change hands, and that's just the ...

Last week

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

3 weeks ago

Paul Biondi's track record at Bristol-Myers covered billions in deals of every shape and size. Here's the complete ...

Last month

Don't missSee all

BioMarin execs discuss some eye-popping numbers for the price of valrox — but haven't we heard this before?

4 days ago

#JPM20: Five years after first PCSK9, Novartis goes for win as Sanofi moves on, Amgen salvages what's left

4 days ago

#JPM20: After a year of NASH collapses, all eyes on two biotechs

4 days ago

Nektar abandons opioid drug after a unanimous 27-0 rebuff from FDA adcomm

6 days ago

Endpoints Standouts

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

3 weeks ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

2 months ago

Unlock the full Endpoints experience for your company — and support our mission of independent biopharma reporting

Last month

Publisher's note

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

3 months ago

Peer review See all

Jan

10

Eli Lilly vet jumps aboard Polaris Partners; Mirati shakes up its leadership team with new hires and promotions

Jan

3

IQVIA vet takes the helm at China's Fountain Medical; Michael Nazak promoted to CFO post at Aridis

Dec

20

Bill Lundberg takes over the reins at Merus; Former Akcea COO Jeffrey Goldberg takes the helm of Immunitas

Dec

13

Shehnaaz Suliman dives back into Alzheimer's at Alector; Pyxis recruits SpringWorks founder Lara Sullivan as CEO

Dec

6

Ex-Celgene exec Terrie Curran puts her Phathom team in place; Caraway taps Martin Williams as CEO

R&D channel feed

4 days ago

The FDA: Faster, but not necessarily better. And that could threaten the agency's brand

Faster FDA drug approvals may reflect less rigorous evidentiary standards, a new analysis suggests. In 1962, the regulatory scrutiny of medicines by the FDA intensified in reaction ...

READ MORE

Four years after 'moonshot' launch, Patrick Soon-Shiong has a big reveal: a single patient

6 days ago

#JPM20: 'The NPV is always wrong.' Takeda preps another spinout — this time on psych

6 days ago

latest in R&D

‘Clinical superiority’: diazepam nasal spray illustrates FDA parameters for orphan drug exclusivity

6 days ago

Another opioid pain drug, really? FDA staff sound sour on Nektar analgesic

Last week

Amarin's Vascepa reigns supreme in fish oil battle, as AstraZeneca's rival fizzles

Last week

That company suing Patrick Soon-Shiong for $1B? Someone's trying to buy it for $1B

Last week

Targeting the BFPs of the CNS, Biogen licenses map of genetic neighborhoods in the brain

Last week

see latest stories

Pharma channel feed

4 days ago

GSK, Pfizer contradict on the future of consumer health JV — report

It appears GSK and Pfizer — who run a consumer health JV together — forgot to get their story straight ahead of this year's JP Morgan conference. On Tuesday, Pfizer chief Albert ...

READ MORE

AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study

6 days ago

Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report

6 days ago

latest in Pharma

Alexis Borisy has $200M to back a market-based plan aimed at curing America’s drug pricing ‘sickness’

Last week

J&J plans to recruit a new generation of 'bilingual' scientists for a research facility blueprinted for the booming Bay Area

Last week

Blueprint scores first FDA OK for a precision GIST cancer drug, just ahead of a rival treatment. And the price is a big surprise

Last week

Merck's Keytruda wins another first — this time for an FDA nod to treat a subset of bladder cancer patients

Last week

Steepest decline in US cancer mortality ever recorded, study finds

Last week

see latest stories